オーリニア・ファーマシューティカルズ
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.29 | $83M | $52M |
| 2026 Q1 | 0.26 | $78M | $33M |
| 2025 Q4 | 1.58 | $77M | $45M |
| 2025 Q3 | 0.23 | $73M | $44M |
| 2025 Q2 | 0.16 | $70M | $44M |
| 2025 Q1 | 0.16 | $62M | $1M |
| 2024 Q4 |
| 0.01 |
| $60M |
| $30M |
| 2024 Q3 | 0.10 | $68M | $17M |